Latest News

Breakthrough at 2026 AACR! Senhwa Biosciences’ CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy

Mar

17

2026

Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape

Mar

03

2026

Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC “Blockbuster” Therapy

Dec

29

2025

Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference

Dec

23

2025

Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors-BeOne

Dec

11

2025

Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy

Oct

16

2025

Senhwa Biosciences’ CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market

Sep

16

2025

Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value

Sep

05

2025